The SINNR study will evaluate the virologic efficacy (viral load \<50 copies/mL)and safety of STRIBILD administered for 48 weeks to HIV-infected current or recent illicit drug users.
The SINNR study is a pilot, observational, open label study. It will evaluate the virologic efficacy (viral load \<50 copies/mL), safety, and immunologic response of STRIBILD administered for 48 weeks to HIV-infected current or recent illicit drug users. Approximately 30 HIV-infected current or recent illicit drug users (≥19y.o.,\<70y.o.) from Vancouver Infectious Diseases Centre and Regina General Hospital, University of Saskatchewan will be taking an oral 1 STRIBILD tablet once a day for 48 weeks. Additionally, adherence to STRIBILD over 48 weeks and quality of life will be measured in this population.
Study Type
OBSERVATIONAL
Enrollment
30
Taking oral 1 STRIBILD tablet once a day for 48 weeks
Vancouver ID Research and Care Centre Society
Vancouver, British Columbia, Canada
RECRUITINGVirologic Efficacy (viral load <50copies/ml after taking STRIBILD)
Evaluate viral load \<50copies/ml after taking STRIBILD
Time frame: 48 weeks
Safety-Side Effect Profile and Number of Participants with Adverse Events
Evaluate safety of STRIBILD
Time frame: 48 weeks
Immunologic Response-CD4 Cell Count and Change in CD4 Cell Count at 48 Weeks
Evaluate immunologic response of STRIBILD
Time frame: 48 weeks
Adherence
Evaluate Adherence to STRIBILD
Time frame: 48 weeks
Quality of Life
Evaluate Quality of life after taking STRIBILD
Time frame: 48 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.